Pfizer announced Friday that it will provide up to 40 million of its Covid-19 vaccine doses to poorer countries on a non-profit basis, through the globally-pooled Covax facility.
Geneva (AFP): Pfizer announced Friday that it will provide up to 40 million of its Covid-19 vaccine doses to poorer countries on a non-profit basis, through the globally-pooled Covax facility.
While dozens of the world's richer countries have begun their vaccination campaigns in a bid to curb the pandemic, coronavirus jabs have been few and far between in the world's poorer nations.
Covax -- the globally-pooled coronavirus vaccine procurement and equitable distribution effort, aimed at ensuring that lower-income countries get hold of doses too -- is hoping to ship its first deliveries in February.
Covax is co-led by the World Health Organization and Gavi, the Vaccine Alliance. The Pfizer-BioNTech vaccine is the only one so far to have received emergency use approval from the WHO.
Developing countries should have "the same access to vaccines as the rest of the world", Pfizer chairman Albert Bourla told a virtual press conference.
"We will provide the vaccine to Covax for these countries at a not-for-profit basis.
"We are proud to have this opportunity to provide doses that will support Covax's efforts towards vaccinating health care workers at high risk of exposure in developing countries, and other vulnerable populations."
Set up last year, Covax initially aimed to secure enough Covid-19 vaccines this year for the most vulnerable 20 percent in participating countries.
In Covax, funding is covered for the 92 lower- and lower-middle income economies involved, while for richer countries, it operates as a back-up insurance policy.
'Science will win'
Gavi chief executive Seth Berkley said nearly 150 million doses of the AstraZeneca-Oxford vaccine were ready to ship through Covax -- pending emergency use approval from the WHO, which is on course to happen in mid-February.
He said Covax should be able to deliver those doses in the first quarter of 2021.
Covax still needs to finalise a supply agreement for the Pfizer-BioNTech vaccine.
Berkley said Covax could procure 2.3 billion vaccine doses this year, which, he said, would equate to close to 1.8 billion doses for the poorest 92 countries -- enough to vaccinate about 27 percent of the population, an upgrade on the initial target.
Asked about accepting Chinese and Russian vaccines into the Covax programme, Berkley said they would consider any vaccines, "assuming they add value to the portfolio", are proven safe and efficacious and have reasonable pricing and supply allocations.
Speaking more broadly than Covax, Pfizer's Bourla said he felt confident that Pfizer-BioNTech should be able to produce two billion Covid-19 vaccine doses by the end of 2021.
"We are one step closer to ending this global health crisis, proving that science will win, and will win for everyone," he said.
Asked about how many vaccine doses all manufacturers might be able to produce this year, Gavi's Berkley said: "I think we're talking about numbers in the range of six to seven billion doses".
WHO director-general Tedros Adhanom Ghebreyesus called for every vaccine manufacturer to get on board the Covax programme.
"Vaccines are giving us all hope of ending the pandemic and getting the economy on the road to recovery," said Tedros.
"We still have a lot of work to do, but the light at the end of the tunnel continues to grow brighter."